this is what I’m trying to wrap my brain around, we know there were at least 87 deaths, and there were 62 critical patients, of which 24% fewer died on the leronlimab arm than the placebo. That means there were deaths in the severe patients. Is it even possible that leronlimab did not show enough improvement in the severe patients if it was able to reduce the mortality in critical patients? How can this PR be missing this crucial info?